|
|
|
|
| LEADER |
01000caa a22002652 4500 |
| 001 |
NLM263168298 |
| 003 |
DE-627 |
| 005 |
20250220122558.0 |
| 007 |
cr uuu---uuuuu |
| 008 |
231224s2016 xx |||||o 00| ||eng c |
| 024 |
7 |
|
|a 10.1016/j.clim.2016.08.003
|2 doi
|
| 028 |
5 |
2 |
|a pubmed25n0877.xml
|
| 035 |
|
|
|a (DE-627)NLM263168298
|
| 035 |
|
|
|a (NLM)27496090
|
| 035 |
|
|
|a (PII)S1521-6616(16)30259-5
|
| 040 |
|
|
|a DE-627
|b ger
|c DE-627
|e rakwb
|
| 041 |
|
|
|a eng
|
| 100 |
1 |
|
|a Cobo-Calvo, Álvaro
|e verfasserin
|4 aut
|
| 245 |
1 |
0 |
|a Leukocyte adhesion molecule dynamics after Natalizumab withdrawal in Multiple Sclerosis
|
| 264 |
|
1 |
|c 2016
|
| 336 |
|
|
|a Text
|b txt
|2 rdacontent
|
| 337 |
|
|
|a ƒaComputermedien
|b c
|2 rdamedia
|
| 338 |
|
|
|a ƒa Online-Ressource
|b cr
|2 rdacarrier
|
| 500 |
|
|
|a Date Completed 31.05.2017
|
| 500 |
|
|
|a Date Revised 21.03.2022
|
| 500 |
|
|
|a published: Print-Electronic
|
| 500 |
|
|
|a Citation Status MEDLINE
|
| 520 |
|
|
|a Copyright © 2016 Elsevier Inc. All rights reserved.
|
| 520 |
|
|
|a Cell-adhesion molecules (CAMs) dynamics in Multiple Sclerosis (MS) patients have been widely studied after Natalizumab (NTZ) introduction. However, their temporal dynamics after NTZ withdrawal (NTZ-W) has not been described. We prospectively evaluate changes in the expression levels of CAMs (CD49d, CD29, L-Selectin and CD11a) involved in T cell migration of 22 MS patients after NTZ-W. CD49d, CD29 and CD11a expression experienced a continuous increase expression two months after NTZ-W and Cd49d expression at month six after NTZ-W correlated to NTZ treatment duration, both in CD45+CD4+ and CD45+CD8+. CD49d expression up to month three after NTZ-W was related to MS activity in CD45+CD8+ at the end of the study. Results from this study suggest that patients with a longer NTZ treatment are more susceptible to present a "molecular rebound" after NTZ-W. CD49d determination may be a useful tool to closely monitor MS activity in patients who interrupt NTZ
|
| 650 |
|
4 |
|a Journal Article
|
| 650 |
|
4 |
|a Observational Study
|
| 650 |
|
4 |
|a Adhesion molecules
|
| 650 |
|
4 |
|a Dynamics
|
| 650 |
|
4 |
|a Multiple Sclerosis
|
| 650 |
|
4 |
|a Natalizumab withdrawal
|
| 650 |
|
4 |
|a VLA-4
|
| 650 |
|
7 |
|a Antigens, CD
|2 NLM
|
| 650 |
|
7 |
|a Cell Adhesion Molecules
|2 NLM
|
| 650 |
|
7 |
|a Immunologic Factors
|2 NLM
|
| 650 |
|
7 |
|a Integrin alpha4beta1
|2 NLM
|
| 650 |
|
7 |
|a Natalizumab
|2 NLM
|
| 700 |
1 |
|
|a Figueras, Agnes
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Bau, Laura
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Matas, Elisabet
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Mañé Martínez, María Alba
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a León, Isabel
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Majòs, Carles
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Romero-Pinel, Lucia
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Martínez-Yélamos, Sergio
|e verfasserin
|4 aut
|
| 773 |
0 |
8 |
|i Enthalten in
|t Clinical immunology (Orlando, Fla.)
|d 1999
|g 171(2016) vom: 05. Okt., Seite 18-24
|w (DE-627)NLM098196855
|x 1521-7035
|7 nnns
|
| 773 |
1 |
8 |
|g volume:171
|g year:2016
|g day:05
|g month:10
|g pages:18-24
|
| 856 |
4 |
0 |
|u http://dx.doi.org/10.1016/j.clim.2016.08.003
|3 Volltext
|
| 912 |
|
|
|a GBV_USEFLAG_A
|
| 912 |
|
|
|a SYSFLAG_A
|
| 912 |
|
|
|a GBV_NLM
|
| 912 |
|
|
|a GBV_ILN_11
|
| 912 |
|
|
|a GBV_ILN_24
|
| 912 |
|
|
|a GBV_ILN_350
|
| 951 |
|
|
|a AR
|
| 952 |
|
|
|d 171
|j 2016
|b 05
|c 10
|h 18-24
|